Thera-SAbDab

ONARTUZUMAB

> Structural Summary

Therapeutic	Onartuzumab
Target	MET
Heavy Chain	EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK
100% seqID Fv Structure	4k3j [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	4k3j [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Fab + di-Fc
Isotype	G1
Highest Clinical Trial (June '19)	Phase-III
Estimated Status (June '19)	Discontinued
Recorded Developmental Technology	na
INN Year Proposed	2010
INN Year Recommended	2011
Companies Involved	Chugai Pharmaceutical, Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Breast cancer, Colorectal cancer, Gastric cancer, Glioblastoma, Liver cancer, Non-small cell lung cancer, Solid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]